Jantung yang Tidak Tahu Sedang Diobati: Kardiotoksisitas Anthracycline dan Urgensi Kardio-Onkologi
MEDICINUS · 01.06.2026 · 39 (6) · 3-6
DOI: 10.56951/49s0cn95 ↗Kurz gefasst
Fachartikel in der Zeitschrift MEDICINUS, online erschienen am 01.06.2026. Verfasst von Raymond R. Tjandrawinata. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Anthracycline-based chemotherapy has long been a cornerstone in the management of various malignancies, however, this antineoplastic class carries a frequently under-recognized consequence in the form of subclinical cardiac injury thatdevelops long before clinical manifestations become apparent. Cardiotoxicity mediated by topoisomerase IIβ dysregulation and oxidative stress does not occur abruptly, but cumulatively, with an incidence of approximately 9% among exposed populations. The physiological paradox further complicates this phenomenon, as compensatory mechanisms may mask ongoing myocardial damage, allowing early intervention window to be frequently missed. This article argues that the traditional boundaries between oncology and cardiology are no longer sufficient, and that an integrated cardio-oncology approach, incorporating active cardiac surveillance as soon as the initiation of therapy, should be regarded as clinical necessity rather than merely a consultative option.
Zitieren
APA
Tjandrawinata, R. R. (2026). Jantung yang Tidak Tahu Sedang Diobati: Kardiotoksisitas Anthracycline dan Urgensi Kardio-Onkologi. MEDICINUS, 39(6), 3-6. https://doi.org/10.56951/49s0cn95
Vancouver
Tjandrawinata RR. Jantung yang Tidak Tahu Sedang Diobati: Kardiotoksisitas Anthracycline dan Urgensi Kardio-Onkologi. MEDICINUS. 2026;39(6):3-6. doi:10.56951/49s0cn95
BibTeX
@article{Tjandrawinata2026,
author = {Tjandrawinata, Raymond R.},
title = {Jantung yang Tidak Tahu Sedang Diobati: Kardiotoksisitas Anthracycline dan Urgensi Kardio-Onkologi},
journal = {MEDICINUS},
year = {2026},
volume = {39},
number = {6},
pages = {3--6},
doi = {10.56951/49s0cn95}
}
EUVIMED